April 16, 2014

Kolltan Pharmaceuticals Expands Company's Board of Directors
Kolltan Elects Daniel R. Vlock, M.D., as Director and Appoints William S. Slattery as Board Observer

View More



March 26, 2014

Kolltan Pharmaceuticals Obtains $60 Million in Series D Financing
Proceeds Will Advance Proprietary Biologic Product Candidates Targeting Receptor Tyrosine Kinases

View More



January 21, 2014

Kolltan Pharmaceuticals Initiates Phase 1 Study of KTN3379, A Dual-Mechanism Anti-ErbB3 Monoclonal Antibody
First Cancer Patient Treated at the Karmanos Cancer Center

View More



December 6, 2013

Kolltan Pharmaceuticals Licenses Novel anti-KIT Antibodies and Related Intellectual Property from the University of Toronto

View More



September 9, 2013

Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
Kolltan Also Appoints Paul Medeiros to the Company’s Board of Directors and Appoints Roy S. Herbst, M.D., Ph.D., and Thomas Mehr

View More



July 29, 2013

Kolltan Enters into License and Option Agreement with MedImmune

View More



July 18, 2013

Kolltan and The Children's Hospital of Philadelphia to Initiate Collaboration in Pediatric Neuroblastoma
Kolltan Obtains Exclusive License for Intellectual Property Related to Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma

View More



April 2, 2013

Kolltan Pharmaceuticals Expands Senior Management Team, Appoints Theresa M. LaVallee, Ph.D., as Vice President, Translational Medicine

View More



February 13, 2013

Kolltan Pharmaceuticals Expands Senior Management Team, Appoints Jane Henderson as Senior Vice President & Chief Business Officer

View More



April 23, 2012

Kolltan Pharmaceuticals Appoints Gerald McMahon, Ph.D., President & Chief Executive Officer
Kolltan Focused on Oncology and Other Serious Diseases, Based on Innovative Drug Targets

View More



April 11, 2012

Michael Schmertzler Completes Tenure as Chief Executive Officer of Kolltan Pharmaceuticals

View More



January 19, 2010

Kolltan Pharmaceuticals Closes $10 Million Series B Related Financing
Company Has Raised a Total of $50 Million Since Inception

View More



August 18, 2009

Kolltan Pharmaceuticals Expands Board of Directors and Senior Executive Team
Kolltan announced today the election of four external members to its Board of Directors and two new officers

View More



August 18, 2009

Kolltan Pharmaceuticals Adds $5 Million to Close Series A Financing
Kolltan closes its Series A preferred stock financing at $40 million

View More



August 6th, 2009

Kolltan Founder, Board Member and Chairman of Scientific Advisory Board Publishes Article on Receptor Tyrosine Kinase Signaling

View More



August 5, 2009

Kolltan Pharmaceuticals Opens Office and R&D Facility
in New Haven, Connecticut

View More



January 8, 2009

Kolltan Pharmaceuticals Raises over $35 Million in Series A Financing
Proceeds to Fund Development Programs and Support Expansion of Senior Team

View More



January 8, 2009

Michael Schmertzler Joins Kolltan Pharmaceuticals as CEO and Director
Yaron Hadari, Ph.D., Named Vice President of Research

View More